Characterization of CHO-K1 cells stably expressing PDE-IV enzymes View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-02

AUTHORS

D. J. Pon, M. Plant, J. Tkach, L. Boulet, E. Muise, R. A. Allen, I. W. Rodger

ABSTRACT

A CHO-K1 cell line stably expressing a recombinant full-length human PDE-IVa (HSPDE4A4B) enzyme was established under hygromycin B selection. Full-length expression of the protein was determined by Western blot analysis, which revealed the presence of a 125-kDa immunoreactive band using rabbit anti-PDE-IVa antibodies. The potency of inhibitor compounds was examined by their ability to increase cAMP in the whole-cell, and by their ability to inhibit cAMP hydrolysis in a 100,000 g supernatant (soluble enzyme preparation) obtained from the same cell line. Inhibition of the expressed PDE-IVa activity by selective PDE-IV inhibitors--(R) and (S)-rolipram, RS 14203, and CDP 840--at 100 nM substrate demonstrated that RS 14203 and CDP 840 were the most potent with IC50 = 9 nM, followed by (R)-rolipram (IC50 = 110 nM) and (S)-rolipram (IC50 = 420 nM). The rank order of potencies of the inhibitors in elevating cAMP in the whole-cell assay was quite different from that on the soluble enzyme. RS 14203 was still the most potent compound in elevating cAMP. Moreover, the relative rank order of potencies between CDP 840 and (R)-rolipram changed dramatically, such that (R)-rolipram was more potent than CDP 840 = (S)-rolipram. An apparent 30-fold stereoselectivity between (R)- and (S)-rolipram was also noted. The whole-cell rank order of potencies was also maintained when PKA activity ratios were measured in place of cAMP levels. The ability of the compounds to elevate cAMP in the stable CHO-K1 cells appeared to track better with the potency of the compounds against the high-affinity (Sr) conformer of the enzyme rather than the low-affinity catalytic state. More... »

PAGES

159-178

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02737834

DOI

http://dx.doi.org/10.1007/bf02737834

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006243177

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9631244


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "3',5'-Cyclic-AMP Phosphodiesterases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CHO Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Catalysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cricetinae", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclic AMP", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclic Nucleotide Phosphodiesterases, Type 4", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Activation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Eosinophils", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Guinea Pigs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydrolysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphodiesterase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transfection", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Merck (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.292545.d", 
          "name": [
            "Department of Pharmacology, Merck Frosst Center for Therapeutic Research, 16711 Trans Canada Hwy, H9H 3L1, Kirkland, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pon", 
        "givenName": "D. J.", 
        "id": "sg:person.01220165314.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220165314.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.292545.d", 
          "name": [
            "Department of Pharmacology, Merck Frosst Center for Therapeutic Research, 16711 Trans Canada Hwy, H9H 3L1, Kirkland, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Plant", 
        "givenName": "M.", 
        "id": "sg:person.01363206674.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363206674.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.292545.d", 
          "name": [
            "Department of Pharmacology, Merck Frosst Center for Therapeutic Research, 16711 Trans Canada Hwy, H9H 3L1, Kirkland, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tkach", 
        "givenName": "J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.292545.d", 
          "name": [
            "Department of Pharmacology, Merck Frosst Center for Therapeutic Research, 16711 Trans Canada Hwy, H9H 3L1, Kirkland, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boulet", 
        "givenName": "L.", 
        "id": "sg:person.0645356744.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645356744.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.292545.d", 
          "name": [
            "Department of Pharmacology, Merck Frosst Center for Therapeutic Research, 16711 Trans Canada Hwy, H9H 3L1, Kirkland, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Muise", 
        "givenName": "E.", 
        "id": "sg:person.01136763405.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136763405.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UCB Pharma (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418727.f", 
          "name": [
            "Celltech Therapeutics, SL1 4EN, Slough, Berkshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Allen", 
        "givenName": "R. A.", 
        "id": "sg:person.0670051063.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670051063.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.292545.d", 
          "name": [
            "Department of Pharmacology, Merck Frosst Center for Therapeutic Research, 16711 Trans Canada Hwy, H9H 3L1, Kirkland, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodger", 
        "givenName": "I. W.", 
        "id": "sg:person.01103762036.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103762036.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00168758", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003426398", 
          "https://doi.org/10.1007/bf00168758"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00168758", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003426398", 
          "https://doi.org/10.1007/bf00168758"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2999(94)90107-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003960850"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2999(94)90107-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003960850"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0091-3057(94)00296-u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010077833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.95.08071179", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015172837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.1995.tb16317.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027881305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.1996.tb15450.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030063040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2999(86)90210-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046723956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2999(86)90210-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046723956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.95.08030457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052601544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077286380", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077299738", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079793630", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082377115", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082393303", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082509170", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1998-02", 
    "datePublishedReg": "1998-02-01", 
    "description": "A CHO-K1 cell line stably expressing a recombinant full-length human PDE-IVa (HSPDE4A4B) enzyme was established under hygromycin B selection. Full-length expression of the protein was determined by Western blot analysis, which revealed the presence of a 125-kDa immunoreactive band using rabbit anti-PDE-IVa antibodies. The potency of inhibitor compounds was examined by their ability to increase cAMP in the whole-cell, and by their ability to inhibit cAMP hydrolysis in a 100,000 g supernatant (soluble enzyme preparation) obtained from the same cell line. Inhibition of the expressed PDE-IVa activity by selective PDE-IV inhibitors--(R) and (S)-rolipram, RS 14203, and CDP 840--at 100 nM substrate demonstrated that RS 14203 and CDP 840 were the most potent with IC50 = 9 nM, followed by (R)-rolipram (IC50 = 110 nM) and (S)-rolipram (IC50 = 420 nM). The rank order of potencies of the inhibitors in elevating cAMP in the whole-cell assay was quite different from that on the soluble enzyme. RS 14203 was still the most potent compound in elevating cAMP. Moreover, the relative rank order of potencies between CDP 840 and (R)-rolipram changed dramatically, such that (R)-rolipram was more potent than CDP 840 = (S)-rolipram. An apparent 30-fold stereoselectivity between (R)- and (S)-rolipram was also noted. The whole-cell rank order of potencies was also maintained when PKA activity ratios were measured in place of cAMP levels. The ability of the compounds to elevate cAMP in the stable CHO-K1 cells appeared to track better with the potency of the compounds against the high-affinity (Sr) conformer of the enzyme rather than the low-affinity catalytic state.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf02737834", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1090910", 
        "issn": [
          "1085-9195", 
          "1559-0283"
        ], 
        "name": "Cell Biochemistry and Biophysics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1-2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "name": "Characterization of CHO-K1 cells stably expressing PDE-IV enzymes", 
    "pagination": "159-178", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1dbd1da1dd3c3f2e9512b4d1451633e8bedafebcc712dc6566c106a4e0c9883c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9631244"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9701934"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02737834"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006243177"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02737834", 
      "https://app.dimensions.ai/details/publication/pub.1006243177"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000370_0000000370/records_46751_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF02737834"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02737834'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02737834'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02737834'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02737834'


 

This table displays all metadata directly associated to this object as RDF triples.

210 TRIPLES      21 PREDICATES      58 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02737834 schema:about N0538cee8bca947bd9524e0260cd0826c
2 N22aa6c69df9b478986c983a08ef4e7a5
3 N25393eaaf9c848b2a7186c760ec5623e
4 N391d38753fd14d3091ce69ad46c341e5
5 N3a46817ef4ce4dc3b127b2b15dd18f65
6 N56187c0ee3e6409ab34723557264a5ef
7 N5a2931b177514b4e8b29b88823d6b771
8 N5c63b652a9e84e3ea9450dae74c4e269
9 N6e7d1165e6b841c59653769cb1c2d862
10 Nd66859ba5c7f498485120c94b1cb7976
11 Ndaac11e6282b4eaea7039949ba2b216e
12 Ne70a8112cecc4881b422a3c1ef21e81d
13 Ne9041fd8adcb4c99a8f0939c6492e628
14 Nf1119b4e9c714ff7bcae17cf36604dcb
15 Nfd75a1ec652e4acea2ad958f9880e2f9
16 anzsrc-for:06
17 anzsrc-for:0601
18 schema:author N317ca9ed872449b78b58feca2e94f356
19 schema:citation sg:pub.10.1007/bf00168758
20 https://app.dimensions.ai/details/publication/pub.1077286380
21 https://app.dimensions.ai/details/publication/pub.1077299738
22 https://app.dimensions.ai/details/publication/pub.1079793630
23 https://app.dimensions.ai/details/publication/pub.1082377115
24 https://app.dimensions.ai/details/publication/pub.1082393303
25 https://app.dimensions.ai/details/publication/pub.1082509170
26 https://doi.org/10.1016/0014-2999(86)90210-4
27 https://doi.org/10.1016/0014-2999(94)90107-4
28 https://doi.org/10.1016/0091-3057(94)00296-u
29 https://doi.org/10.1111/j.1476-5381.1995.tb16317.x
30 https://doi.org/10.1111/j.1476-5381.1996.tb15450.x
31 https://doi.org/10.1183/09031936.95.08030457
32 https://doi.org/10.1183/09031936.95.08071179
33 schema:datePublished 1998-02
34 schema:datePublishedReg 1998-02-01
35 schema:description A CHO-K1 cell line stably expressing a recombinant full-length human PDE-IVa (HSPDE4A4B) enzyme was established under hygromycin B selection. Full-length expression of the protein was determined by Western blot analysis, which revealed the presence of a 125-kDa immunoreactive band using rabbit anti-PDE-IVa antibodies. The potency of inhibitor compounds was examined by their ability to increase cAMP in the whole-cell, and by their ability to inhibit cAMP hydrolysis in a 100,000 g supernatant (soluble enzyme preparation) obtained from the same cell line. Inhibition of the expressed PDE-IVa activity by selective PDE-IV inhibitors--(R) and (S)-rolipram, RS 14203, and CDP 840--at 100 nM substrate demonstrated that RS 14203 and CDP 840 were the most potent with IC50 = 9 nM, followed by (R)-rolipram (IC50 = 110 nM) and (S)-rolipram (IC50 = 420 nM). The rank order of potencies of the inhibitors in elevating cAMP in the whole-cell assay was quite different from that on the soluble enzyme. RS 14203 was still the most potent compound in elevating cAMP. Moreover, the relative rank order of potencies between CDP 840 and (R)-rolipram changed dramatically, such that (R)-rolipram was more potent than CDP 840 = (S)-rolipram. An apparent 30-fold stereoselectivity between (R)- and (S)-rolipram was also noted. The whole-cell rank order of potencies was also maintained when PKA activity ratios were measured in place of cAMP levels. The ability of the compounds to elevate cAMP in the stable CHO-K1 cells appeared to track better with the potency of the compounds against the high-affinity (Sr) conformer of the enzyme rather than the low-affinity catalytic state.
36 schema:genre research_article
37 schema:inLanguage en
38 schema:isAccessibleForFree false
39 schema:isPartOf Na5b5d92f79024b0591ad8b046a54aab6
40 Nf752f5ba5c2d4b0ba48c53bf491ac0b2
41 sg:journal.1090910
42 schema:name Characterization of CHO-K1 cells stably expressing PDE-IV enzymes
43 schema:pagination 159-178
44 schema:productId N3c027630c82c4378a4203ad0abf7448d
45 N49c064e24c524cd898fc4a00463b722c
46 Na3d6196185c84c1ca8058eda2ed61567
47 Na57990c177d843ef8b2205c370ef18eb
48 Nd9251b455ca04f38a6f7557304a328c1
49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006243177
50 https://doi.org/10.1007/bf02737834
51 schema:sdDatePublished 2019-04-11T13:29
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher N172221a8ff2b4f69b87cd472a0b9c1da
54 schema:url http://link.springer.com/10.1007/BF02737834
55 sgo:license sg:explorer/license/
56 sgo:sdDataset articles
57 rdf:type schema:ScholarlyArticle
58 N0538cee8bca947bd9524e0260cd0826c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Guinea Pigs
60 rdf:type schema:DefinedTerm
61 N172221a8ff2b4f69b87cd472a0b9c1da schema:name Springer Nature - SN SciGraph project
62 rdf:type schema:Organization
63 N1bef6910a8b54491a80b7a58d1625349 schema:affiliation https://www.grid.ac/institutes/grid.292545.d
64 schema:familyName Tkach
65 schema:givenName J.
66 rdf:type schema:Person
67 N22aa6c69df9b478986c983a08ef4e7a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Eosinophils
69 rdf:type schema:DefinedTerm
70 N25393eaaf9c848b2a7186c760ec5623e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Animals
72 rdf:type schema:DefinedTerm
73 N317ca9ed872449b78b58feca2e94f356 rdf:first sg:person.01220165314.93
74 rdf:rest N3788cef4b9e047ffa9f32d6f03d2d071
75 N3788cef4b9e047ffa9f32d6f03d2d071 rdf:first sg:person.01363206674.76
76 rdf:rest Nff988c15315344c88195811c1a812fa9
77 N391d38753fd14d3091ce69ad46c341e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Transfection
79 rdf:type schema:DefinedTerm
80 N3a46817ef4ce4dc3b127b2b15dd18f65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Recombinant Proteins
82 rdf:type schema:DefinedTerm
83 N3c027630c82c4378a4203ad0abf7448d schema:name nlm_unique_id
84 schema:value 9701934
85 rdf:type schema:PropertyValue
86 N49c064e24c524cd898fc4a00463b722c schema:name dimensions_id
87 schema:value pub.1006243177
88 rdf:type schema:PropertyValue
89 N56187c0ee3e6409ab34723557264a5ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Enzyme Activation
91 rdf:type schema:DefinedTerm
92 N5a2931b177514b4e8b29b88823d6b771 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Cyclic Nucleotide Phosphodiesterases, Type 4
94 rdf:type schema:DefinedTerm
95 N5c63b652a9e84e3ea9450dae74c4e269 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Humans
97 rdf:type schema:DefinedTerm
98 N6e7d1165e6b841c59653769cb1c2d862 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Phosphodiesterase Inhibitors
100 rdf:type schema:DefinedTerm
101 N80a58d08a9db49aea8c4085922e19cb7 rdf:first sg:person.01103762036.99
102 rdf:rest rdf:nil
103 N9bac23f656374c928578c13e1750f292 rdf:first sg:person.01136763405.80
104 rdf:rest Nb3ae5d04b7d74fad994f865c53c03587
105 Na3d6196185c84c1ca8058eda2ed61567 schema:name readcube_id
106 schema:value 1dbd1da1dd3c3f2e9512b4d1451633e8bedafebcc712dc6566c106a4e0c9883c
107 rdf:type schema:PropertyValue
108 Na57990c177d843ef8b2205c370ef18eb schema:name doi
109 schema:value 10.1007/bf02737834
110 rdf:type schema:PropertyValue
111 Na5b5d92f79024b0591ad8b046a54aab6 schema:issueNumber 1-2
112 rdf:type schema:PublicationIssue
113 Nb3ae5d04b7d74fad994f865c53c03587 rdf:first sg:person.0670051063.97
114 rdf:rest N80a58d08a9db49aea8c4085922e19cb7
115 Nd66859ba5c7f498485120c94b1cb7976 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name 3',5'-Cyclic-AMP Phosphodiesterases
117 rdf:type schema:DefinedTerm
118 Nd9251b455ca04f38a6f7557304a328c1 schema:name pubmed_id
119 schema:value 9631244
120 rdf:type schema:PropertyValue
121 Ndaac11e6282b4eaea7039949ba2b216e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Cricetinae
123 rdf:type schema:DefinedTerm
124 Ndad9052b84164b4faac88b9954eed9fb rdf:first sg:person.0645356744.32
125 rdf:rest N9bac23f656374c928578c13e1750f292
126 Ne70a8112cecc4881b422a3c1ef21e81d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Hydrolysis
128 rdf:type schema:DefinedTerm
129 Ne9041fd8adcb4c99a8f0939c6492e628 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name CHO Cells
131 rdf:type schema:DefinedTerm
132 Nf1119b4e9c714ff7bcae17cf36604dcb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Cyclic AMP
134 rdf:type schema:DefinedTerm
135 Nf752f5ba5c2d4b0ba48c53bf491ac0b2 schema:volumeNumber 29
136 rdf:type schema:PublicationVolume
137 Nfd75a1ec652e4acea2ad958f9880e2f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Catalysis
139 rdf:type schema:DefinedTerm
140 Nff988c15315344c88195811c1a812fa9 rdf:first N1bef6910a8b54491a80b7a58d1625349
141 rdf:rest Ndad9052b84164b4faac88b9954eed9fb
142 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
143 schema:name Biological Sciences
144 rdf:type schema:DefinedTerm
145 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
146 schema:name Biochemistry and Cell Biology
147 rdf:type schema:DefinedTerm
148 sg:journal.1090910 schema:issn 1085-9195
149 1559-0283
150 schema:name Cell Biochemistry and Biophysics
151 rdf:type schema:Periodical
152 sg:person.01103762036.99 schema:affiliation https://www.grid.ac/institutes/grid.292545.d
153 schema:familyName Rodger
154 schema:givenName I. W.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103762036.99
156 rdf:type schema:Person
157 sg:person.01136763405.80 schema:affiliation https://www.grid.ac/institutes/grid.292545.d
158 schema:familyName Muise
159 schema:givenName E.
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136763405.80
161 rdf:type schema:Person
162 sg:person.01220165314.93 schema:affiliation https://www.grid.ac/institutes/grid.292545.d
163 schema:familyName Pon
164 schema:givenName D. J.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220165314.93
166 rdf:type schema:Person
167 sg:person.01363206674.76 schema:affiliation https://www.grid.ac/institutes/grid.292545.d
168 schema:familyName Plant
169 schema:givenName M.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363206674.76
171 rdf:type schema:Person
172 sg:person.0645356744.32 schema:affiliation https://www.grid.ac/institutes/grid.292545.d
173 schema:familyName Boulet
174 schema:givenName L.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645356744.32
176 rdf:type schema:Person
177 sg:person.0670051063.97 schema:affiliation https://www.grid.ac/institutes/grid.418727.f
178 schema:familyName Allen
179 schema:givenName R. A.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670051063.97
181 rdf:type schema:Person
182 sg:pub.10.1007/bf00168758 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003426398
183 https://doi.org/10.1007/bf00168758
184 rdf:type schema:CreativeWork
185 https://app.dimensions.ai/details/publication/pub.1077286380 schema:CreativeWork
186 https://app.dimensions.ai/details/publication/pub.1077299738 schema:CreativeWork
187 https://app.dimensions.ai/details/publication/pub.1079793630 schema:CreativeWork
188 https://app.dimensions.ai/details/publication/pub.1082377115 schema:CreativeWork
189 https://app.dimensions.ai/details/publication/pub.1082393303 schema:CreativeWork
190 https://app.dimensions.ai/details/publication/pub.1082509170 schema:CreativeWork
191 https://doi.org/10.1016/0014-2999(86)90210-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046723956
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/0014-2999(94)90107-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003960850
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/0091-3057(94)00296-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1010077833
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1111/j.1476-5381.1995.tb16317.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027881305
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1111/j.1476-5381.1996.tb15450.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1030063040
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1183/09031936.95.08030457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052601544
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1183/09031936.95.08071179 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015172837
204 rdf:type schema:CreativeWork
205 https://www.grid.ac/institutes/grid.292545.d schema:alternateName Merck (Canada)
206 schema:name Department of Pharmacology, Merck Frosst Center for Therapeutic Research, 16711 Trans Canada Hwy, H9H 3L1, Kirkland, Quebec, Canada
207 rdf:type schema:Organization
208 https://www.grid.ac/institutes/grid.418727.f schema:alternateName UCB Pharma (United Kingdom)
209 schema:name Celltech Therapeutics, SL1 4EN, Slough, Berkshire, UK
210 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...